SCHEMBL5658916

SCHEMBL5658916

COc1cccc(N2C(=O)C(c3cc(C)c(N)c(C)c3)(c3cc(C)c(O)c(C)c3)c3ccccc32)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.40
MGLL Q99685 1/20 0.39
SCN9A Q15858 1/20 0.37
ALDH1A1 P00352 5/20 0.37
KDM4E B2RXH2 1/20 0.37
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
SMN1; SMN2 Q16637 3/20 0.36
GAA P10253 1/20 0.36
GFER P55789 1/20 0.36
CBX7 O95931 1/20 0.36
CDYL2 Q8N8U2 1/20 0.36
CDYL Q9Y232 1/20 0.36
CDY1; CDY1B Q9Y6F8 1/20 0.36
RAB9A P51151 1/20 0.35
BACE1 P56817 1/20 0.35
BACE2 Q9Y5Z0 1/20 0.35
CYP1A2 P05177 1/20 0.35
HPGD P15428 1/20 0.35
CNR1 P21554 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5656443 0.95 MAPT (0.44) MAPTMGLLSCN9AALDH1A1KDM4E
SCHEMBL5660432 0.93 SCN9A (0.38) MAPTMGLLSCN9AALDH1A1KDM4E
SCHEMBL5662112 0.92 MAPT (0.41) MAPTMGLLSCN9AALDH1A1KDM4E
SCHEMBL5660840 0.91 MAPT (0.38) MAPTMGLLSCN9AALDH1A1KDM4E
SCHEMBL5661100 0.91 MAPT (0.41) MAPTMGLLSCN9AALDH1A1KDM4E
SCHEMBL5656731 0.91 MAPT (0.41) MAPTMGLLSCN9AALDH1A1KDM4E
SCHEMBL5658510 0.90 CNR1 (0.46) MAPTMGLLSCN9AALDH1A1KDM4E
SCHEMBL5659434 0.89 MAPT (0.42) MAPTMGLLSCN9AALDH1A1KDM4E
SCHEMBL5661921 0.89 MAPT (0.41) MAPTMGLLSCN9AALDH1A1KDM4E
SCHEMBL5661171 0.87 ADAMTS5 (0.39) MAPTMGLLSCN9AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-20050054712-A1 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054712-A1 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators NR3C2, NR5A1, NR5A2 MAPT 3588/4885MGLL 3012/4885SCN9A 1918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.